Nanochap raises CNY500 million Series C+ led by Gaorong Ventures
The visual brain-computer interface developer has a retinal implant in clinical trials and a cortical system in development.
Nanochap has completed CNY500 million in Series C+ financing led by Gaorong Ventures, the company announced on November 3. PICC Capital Equity Investment, Monolith Capital, C&D Emerging Industry Equity Investment, Dongfang Jiafu, Danhe Capital and Hangzhou Chantou Group participated. Existing investor Legend Capital also reinvested.
The round is Nanochap’s second financing of 2026 and brings its cumulative funding to CNY1 billion. Qifeng Capital acted as the exclusive financial adviser.
The Hangzhou company is advancing two approaches to artificial vision. Its 320-channel E-BCI retinal system has entered GCP clinical trials, and the company reports experience with three patients. A 1,280-channel system designed to stimulate the visual cortex remains in development, with clinical validation planned. The two approaches address different conditions affecting the eye and visual pathway.